Literature DB >> 21850394

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.

S L Harvey1, R L Milne, S A McLachlan, M L Friedlander, K E Birch, P Weideman, D Goldgar, J L Hopper, K A Phillips.   

Abstract

Published studies have reached contradictory conclusions regarding breast cancer risk for women from families segregating a BRCA1 or BRCA2 mutation who do not carry the family-specific mutation. Accurate estimation of breast cancer risk is crucial for appropriate counselling regarding risk management. The aim of this study is to prospectively assess whether breast cancer risk for mutation negative women from families segregating BRCA1 or BRCA2 mutations is greater than for women in the general population. Eligible women were 722 first-, second- and third-degree relatives of a BRCA1 or BRCA2 mutation carrier from 224 mutation positive (128 BRCA1, 96 BRCA2) families, had no personal cancer history at baseline, and had been tested and found not to carry the family-specific mutation. Self-reported family history of cancer, preventive interventions and verified cancer diagnoses were collected at baseline, and every 3 years thereafter. Median follow-up was 6.1 years (range 0.1-12.4 years). Time at risk of breast cancer was censored at cancer diagnosis or risk-reducing surgery. Standardised incidence ratios (SIR) were estimated by comparing observed to population incidences of invasive breast cancer using Australian Cancer Incidence and Mortality Books. Six cases of invasive breast cancer were observed. The estimated SIRs were 1.14 (95% CI: 0.51-2.53) overall (n = 722), 1.29 (95% CI: 0.58-2.88) when restricted to first- and second-degree relatives of an affected mutation carrier (n = 442) and 0.48 (95% CI: 0.12-1.93) when restricted to those with no family history of breast cancer in the non-mutation carrying parental lineage (n = 424). There was no evidence that mutation negative women from families segregating BRCA1 or BRCA2 mutations are at increased risk of breast cancer. Despite this being the largest prospective cohort to assess this issue, moderately increased breast cancer risk (2-fold) cannot be ruled out.

Entities:  

Mesh:

Year:  2011        PMID: 21850394     DOI: 10.1007/s10549-011-1733-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families.

Authors:  Henriette Roed Nielsen; Janne Petersen; Lotte Krogh; Mef Nilbert; Anne-Bine Skytte
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

2.  Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.

Authors:  Bess Levin; Denise Lech; Bernard Friedenson
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

3.  Comparison of the screening practices of unaffected noncarriers under 40 and between 40 and 49 in BRCA1/2 families.

Authors:  Christelle Duprez; Véronique Christophe; Isabelle Milhabet; Aurélie Krzeminski; Claude Adenis; Pascaline Berthet; Jean-Philippe Peyrat; Philippe Vennin
Journal:  J Genet Couns       Date:  2013-01-25       Impact factor: 2.537

4.  Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers.

Authors:  Julia Fehniger; Feng Lin; Mary S Beattie; Galen Joseph; Celia Kaplan
Journal:  J Genet Couns       Date:  2013-05-12       Impact factor: 2.537

5.  BRCA1 Circos: a visualisation resource for functional analysis of missense variants.

Authors:  Ankita Jhuraney; Aneliya Velkova; Randall C Johnson; Bailey Kessing; Renato S Carvalho; Phillip Whiley; Amanda B Spurdle; Maaike P G Vreeswijk; Sandrine M Caputo; Gael A Millot; Ana Vega; Nicolas Coquelle; Alvaro Galli; Diana Eccles; Marinus J Blok; Tuya Pal; Rob B van der Luijt; Marta Santamariña Pena; Susan L Neuhausen; Talia Donenberg; Eva Machackova; Simon Thomas; Maxime Vallée; Fergus J Couch; Sean V Tavtigian; J N Mark Glover; Marcelo A Carvalho; Lawrence C Brody; Shyam K Sharan; Alvaro N Monteiro
Journal:  J Med Genet       Date:  2015-02-02       Impact factor: 6.318

6.  Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.

Authors:  Annelot Baert; Julie Depuydt; Tom Van Maerken; Bruce Poppe; Fransiska Malfait; Tim Van Damme; Sylvia De Nobele; Gianpaolo Perletti; Kim De Leeneer; Kathleen B M Claes; Anne Vral
Journal:  Oncol Rep       Date:  2017-01-25       Impact factor: 3.906

7.  Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.

Authors:  Jacopo Azzollini; Chiara Pesenti; Luca Ferrari; Laura Fontana; Mariarosaria Calvello; Bernard Peissel; Giorgio Portera; Silvia Tabano; Maria Luisa Carcangiu; Paola Riva; Monica Miozzo; Siranoush Manoukian
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

8.  No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.

Authors:  S Guedaoura; S Pelletier; W D Foulkes; P Hamet; J Simard; N Wong; Z El Haffaf; J Chiquette; M Dorval
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

9.  Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation.

Authors:  Sylvie Pelletier; Nora Wong; Zaki El Haffaf; William D Foulkes; Jocelyne Chiquette; Pavel Hamet; Jacques Simard; Michel Dorval
Journal:  Genet Med       Date:  2015-11-05       Impact factor: 8.822

10.  Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.

Authors:  Andrew J Lee; Alex P Cunningham; Marc Tischkowitz; Jacques Simard; Paul D Pharoah; Douglas F Easton; Antonis C Antoniou
Journal:  Genet Med       Date:  2016-04-14       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.